Provided By GlobeNewswire
Last update: May 14, 2024
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS).
NASDAQ:MNOV (7/24/2025, 12:27:43 PM)
1.255
-0.01 (-0.4%)
Find more stocks in the Stock Screener